Waverley Pharma Inc. (FRA:5GZ)
Germany
· Delayed Price · Currency is EUR 0.0060
0.00 (0.00%)
Last updated: Dec 4, 2025, 3:29 PM CET
Waverley Pharma Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 1.51 | 0.48 | 0.41 | 1.25 | 1.75 | 1.38 | Upgrade
|
| Revenue Growth (YoY) | 2016.26% | 15.36% | -66.95% | -28.87% | 27.47% | 18.82% | Upgrade
|
| Cost of Revenue | 0.91 | 0.26 | 0.33 | 0.96 | 1.53 | 1.19 | Upgrade
|
| Gross Profit | 0.59 | 0.21 | 0.08 | 0.28 | 0.22 | 0.18 | Upgrade
|
| Selling, General & Admin | 0.86 | 0.65 | 1.13 | 1.14 | 0.98 | 0.84 | Upgrade
|
| Research & Development | 0.03 | 0.42 | 0.23 | 0.08 | 0.03 | 0.05 | Upgrade
|
| Operating Expenses | 0.9 | 1.08 | 1.36 | 1.22 | 1.01 | 0.89 | Upgrade
|
| Operating Income | -0.3 | -0.86 | -1.28 | -0.94 | -0.79 | -0.71 | Upgrade
|
| Interest Expense | -0.18 | -0.16 | -0.08 | -0.02 | -0 | - | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | -0.04 | -0 | -0.01 | -0.05 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.12 | 0.12 | 0.08 | 0.3 | 0.04 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -0.37 | -0.95 | -1.28 | -0.66 | -0.8 | -0.71 | Upgrade
|
| Asset Writedown | - | - | -0.94 | - | - | - | Upgrade
|
| Pretax Income | -0.37 | -0.95 | -2.22 | -0.66 | -0.8 | -0.71 | Upgrade
|
| Net Income | -0.37 | -0.95 | -2.22 | -0.66 | -0.8 | -0.71 | Upgrade
|
| Net Income to Common | -0.37 | -0.95 | -2.22 | -0.66 | -0.8 | -0.71 | Upgrade
|
| Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 54 | 54 | 54 | 54 | 54 | 54 | Upgrade
|
| EPS (Basic) | -0.01 | -0.02 | -0.04 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.02 | -0.04 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 39.48% | 45.03% | 19.36% | 22.76% | 12.70% | 13.21% | Upgrade
|
| Operating Margin | -19.97% | -181.32% | -311.30% | -75.08% | -44.89% | -51.60% | Upgrade
|
| Profit Margin | -24.38% | -199.23% | -539.70% | -53.26% | -45.44% | -51.32% | Upgrade
|
| EBITDA | -0.22 | -0.85 | -0.96 | -0.83 | -0.76 | -0.7 | Upgrade
|
| EBITDA Margin | -14.92% | -177.78% | -233.19% | -66.44% | -43.28% | -51.01% | Upgrade
|
| D&A For EBITDA | 0.08 | 0.02 | 0.32 | 0.11 | 0.03 | 0.01 | Upgrade
|
| EBIT | -0.3 | -0.86 | -1.28 | -0.94 | -0.79 | -0.71 | Upgrade
|
| EBIT Margin | -19.97% | -181.32% | - | -75.08% | -44.89% | -51.60% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.